Recently, while preparing an updated presentation to the Saint Louis University cardiology fellows on "diastolic dysfunction," the Skeptical Cardiologist came across a document entitled "What Does ...

Please provide your email address to receive an email when new articles are posted on . An AI algorithm for detection of grade 3 diastolic dysfunction received a breakthrough device designation from ...

Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...

Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) ...

Please provide your email address to receive an email when new articles are posted on . Diastolic dysfunction is an independent risk factor for increased mortality risk among patients with systemic ...

While cardiovascular disease (CVD) is more common in young men than in young women, the risk of CVD increases for postmenopausal women, making them nearly as susceptible as men. Menopause typically ...

Our female subjects were slightly older than the male subjects (72.8 ± 7 vs. 67.4 ± 3.3 years of age, p = 0.002) ( Table II). One half of our male subjects had normal diastolic function, whereas mild ...

After the left ventricle of the heart contracts, it must relax efficiently to prepare to refill and supply the body with blood on the next beat. An increasing number of patients -- including nearly ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.

NEW HOPE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...